Developer docs
API playgroundTry for free, no card

Search company profiles

Quantum Genomics

Full company profile

uuid003e16a

Namestring
Quantum Genomics
Company typeenum
Private
Founded yearint
2006
Descriptiontext

Quantum Genomics is a publicly listed French biopharmaceutical company founded in 2006 and headquartered in Paris, focused on developing therapies for unmet medical needs in the field of cardiovascular diseases. The company trades on Euronext Paris under the ticker ALQGC and operates with a small specialized workforce of 11-50 employees, indicating a clinical-stage or early-commercial organizational footprint typical of European small-cap biotech. Corporate leadership is anchored by Chief Executive Officer and Managing Director Jean-Philippe Milon, with Benoît Gueugnon serving as Administrative and Financial Director.

The company's business model centers on proprietary drug development targeting cardiovascular indications, a therapeutic area with significant unmet medical need and large addressable markets. No specific product candidates, pipeline assets, clinical trial milestones, or technological platforms are disclosed in the available input data, limiting visibility into the precise mechanism of value creation. The firm has executed at least one inorganic growth action — the 2007 acquisition of Eurobiobiz for an undisclosed amount — establishing a precedent for M&A-driven capability expansion, though no subsequent transactions are documented.

Capital structure reflects reliance on public equity markets for funding ongoing R&D, consistent with the long development timelines typical of cardiovascular therapeutics. The available financial disclosures are internally inconsistent and contain figures (e.g., revenues in the billions and losses in the trillions) that are not credible for a company of this size and profile, which materially impairs revenue and growth assessment. No named customers, commercial partners, distribution agreements, or end-market segmentation data are disclosed, leaving commercialization strategy and revenue concentration effectively undocumented in the current evidence base.

Short descriptiontext

Quantum Genomics is a publicly listed, Paris-based biopharmaceutical company founded in 2006 that develops therapies for unmet medical needs in cardiovascular diseases, operating with a small specialized team of 11-50 employees under Euronext Paris ticker ALQGC.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersParis, France
HQ citystring
Paris
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cardiovascular therapeutics, hypertension drug development, biopharmaceutical research, heart failure treatments, clinical stage biotechnology
Industry1 code
PRIMARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
Product category
Cardiovascular Therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Affiliate Commissions
TypeAffiliate Referral
Description

NouveauCasino acts as an affiliate, earning commissions when users click affiliate links and complete qualifying actions (registration, deposit) at partnered online casino operators. Commercial agreements are strictly separated from editorial ranking decisions.

savonnerie-plaisant.fr
2Advertising Revenue
TypeAdvertising
Description

The site generates revenue through advertising partnerships with online casino operators, clearly identified as affiliate links.

savonnerie-plaisant.fr
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Quantum Genomics develops therapies for unmet medical needs in the field of cardiovascular diseases. The company focuses on biopharmaceutical research and development of novel drug compounds targeting hypertension and related cardiovascular conditions.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Complete casino testing methodology covering registration, deposits, withdrawals, and customer service evaluation
+1 more record
Product and service1 record
1Cardiovascular disease therapies (pipeline)
CategoryCardiovascular Therapeutics
Description

Therapeutic drug candidates developed for unmet medical needs in cardiovascular disease, targeting hypertension and related cardiovascular conditions. Offered to patients via healthcare providers and through potential pharmaceutical partnerships.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Leading ANJ-licensed online casino operator in France. NouveauCasino provides affiliate traffic and player referrals in exchange for commission on qualified registrations and deposits. Featured extensively in bonus comparisons and casino reviews.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

ANJ-licensed operator offering casino games, poker, and sports betting. NouveauCasino features Unibet in welcome bonus comparisons, payment method guides, and game variety reviews. Affiliate relationship drives player acquisition.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

ANJ-licensed online poker and casino platform popular in France. Featured in bonus guides, KYC testing, and responsible gambling tool comparisons. Affiliate traffic generates commission for NouveauCasino.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

ANJ-licensed casino and sports betting operator. Mentioned in bonus comparisons and payment method guides as a partnered operator receiving affiliate referrals.

5FDJ (Française des Jeux)
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

State-owned lottery and gaming operator with ANJ license. Referenced for responsible gambling features like 'Pause 24h' option and lottery/gaming offerings.

savonnerie-plaisant.fr
Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global pharmaceutical leader with one of the largest cardiovascular franchises (Entresto, etc.). Represents the broad incumbent competitive backdrop against which a small cardiovascular specialist like Quantum Genomics must position.

2Valneva
TypeRegional player
Description

French-listed specialty biotech focused on vaccines and infectious diseases. Comparable to Quantum Genomics as a fellow French-listed small-cap biotech with similar capital-markets dynamics and European biotech operating profile.

3Innate Pharma
TypeRegional player
Description

French-listed clinical-stage biotech developing immuno-oncology therapies. Comparable to Quantum Genomics as a French small-cap listed biotech serving as a relevant benchmark for European biotech capital-raising dynamics.

TypeDirect peer
Description

Swiss-listed specialty pharma focused on cardiovascular and central nervous system therapies with a small, R&D-heavy organization comparable to Quantum Genomics. Both companies target specialty indications with high unmet need and rely on capital markets to fund late-stage development.

TypeRegional player
Description

French-listed clinical-stage biotech headquartered in France. As a fellow small-cap French biotech, Genfit provides a comparable benchmark for capital-markets dynamics, investor base, and European listing economics relevant to Quantum Genomics.

TypeBroad incumbent
Description

Global pharma with a substantial cardiovascular, renal, and metabolism franchise (Farxiga, Brilinta). Represents a key incumbent competitor and a credible acquirer of differentiated cardiovascular assets that Quantum Genomics might seek to develop or partner.

TypeBroad incumbent
Description

Large French private pharmaceutical company with a long-standing cardiovascular franchise. Servier provides a domestic French peer benchmark and represents both a competitor and a potential partner/acquirer for a French-listed cardiovascular specialist like Quantum Genomics.

TypeBroad incumbent
Description

Major pharmaceutical company with an established cardiovascular portfolio (Xarelto/Eliquis franchises). Bayer represents both a competitive threat and a potential strategic acquirer for focused cardiovascular specialists like Quantum Genomics.

TypeRegional player
Description

French-listed clinical-stage biotech developing inflammatory disease therapies. Comparable to Quantum Genomics in size, listed status on Euronext, and small-team European biotech operating model, even though the therapeutic area differs.

TypeEmerging player
Description

US clinical-stage biotech developing therapies for resistant and uncontrolled hypertension — a directly comparable cardiovascular indication to Quantum Genomics' focus. Both companies target high-unmet-need cardiovascular subsegments with novel mechanisms.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Quantum Genomics

Cardiovascular Therapeuticsquantum-genomics.com

Quantum Genomics is a publicly listed, Paris-based biopharmaceutical company founded in 2006 that develops therapies for unmet medical needs in cardiovascular diseases, operating with a small specialized team of 11-50 employees under Euronext Paris ticker ALQGC.

What Quantum Genomics does

Quantum Genomics is a publicly listed French biopharmaceutical company founded in 2006 and headquartered in Paris, focused on developing therapies for unmet medical needs in the field of cardiovascular diseases. The company trades on Euronext Paris under the ticker ALQGC and operates with a small specialized workforce of 11-50 employees, indicating a clinical-stage or early-commercial organizational footprint typical of European small-cap biotech. Corporate leadership is anchored by Chief Executive Officer and Managing Director Jean-Philippe Milon, with Benoît Gueugnon serving as Administrative and Financial Director.

The company's business model centers on proprietary drug development targeting cardiovascular indications, a therapeutic area with significant unmet medical need and large addressable markets. No specific product candidates, pipeline assets, clinical trial milestones, or technological platforms are disclosed in the available input data, limiting visibility into the precise mechanism of value creation. The firm has executed at least one inorganic growth action — the 2007 acquisition of Eurobiobiz for an undisclosed amount — establishing a precedent for M&A-driven capability expansion, though no subsequent transactions are documented.

Capital structure reflects reliance on public equity markets for funding ongoing R&D, consistent with the long development timelines typical of cardiovascular therapeutics. The available financial disclosures are internally inconsistent and contain figures (e.g., revenues in the billions and losses in the trillions) that are not credible for a company of this size and profile, which materially impairs revenue and growth assessment. No named customers, commercial partners, distribution agreements, or end-market segmentation data are disclosed, leaving commercialization strategy and revenue concentration effectively undocumented in the current evidence base.

Quantum Genomics firmographics

Firmographics
Name
Quantum Genomics
Website
https://quantum-genomics.com
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
1–10 employees
Short description
Quantum Genomics is a publicly listed, Paris-based biopharmaceutical company founded in 2006 that develops therapies for unmet medical needs in cardiovascular diseases, operating with a small specialized team of 11-50 employees under Euronext Paris ticker ALQGC.
Ownership category
akta.pro rank

Quantum Genomics industry classification

Industry
Product category
Cardiovascular Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
akta.pro industry
PRIMARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals

Keywords

  • Cardiovascular therapeutics
  • Hypertension drug development
  • Biopharmaceutical research
  • Heart failure treatments
  • Clinical stage biotechnology

Where Quantum Genomics is headquartered

Location

Headquarters

HQ city
Paris
HQ country
France
HQ region
Europe

Offices1 record

Markets served

Quantum Genomics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Affiliate Commissions: NouveauCasino acts as an affiliate, earning commissions when users click affiliate links and complete qualifying actions (registration, deposit) at partnered online casino operators. Commercial agreements are strictly separated from editorial ranking decisions.
  2. Advertising Revenue: The site generates revenue through advertising partnerships with online casino operators, clearly identified as affiliate links.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Quantum Genomics product offering

Product offering

Core offering

Quantum Genomics develops therapies for unmet medical needs in the field of cardiovascular diseases. The company focuses on biopharmaceutical research and development of novel drug compounds targeting hypertension and related cardiovascular conditions.

Differentiator

Problem solved

Functional benefit

Products and services

  • Cardiovascular disease therapies (pipeline) Therapeutic drug candidates developed for unmet medical needs in cardiovascular disease, targeting hypertension and related cardiovascular conditions. Offered to patients via healthcare providers and through potential pharmaceutical partnerships.

Quantifiable outcome

  • Complete casino testing methodology covering registration, deposits, withdrawals, and customer service evaluation
  • +1 more outcomes

Companies that use Quantum Genomics

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Quantum Genomics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Quantum Genomics partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • BetcliccoreChannel Partner/ Reseller/ DistributorLeading ANJ-licensed online casino operator in France. NouveauCasino provides affiliate traffic and player referrals in exchange for commission on qualified registrations and deposits. Featured extensively in bonus comparisons and casino reviews.
  • UnibetcoreChannel Partner/ Reseller/ DistributorANJ-licensed operator offering casino games, poker, and sports betting. NouveauCasino features Unibet in welcome bonus comparisons, payment method guides, and game variety reviews. Affiliate relationship drives player acquisition.
  • WinamaxcoreChannel Partner/ Reseller/ DistributorANJ-licensed online poker and casino platform popular in France. Featured in bonus guides, KYC testing, and responsible gambling tool comparisons. Affiliate traffic generates commission for NouveauCasino.
  • BwinminorChannel Partner/ Reseller/ DistributorANJ-licensed casino and sports betting operator. Mentioned in bonus comparisons and payment method guides as a partnered operator receiving affiliate referrals.
  • FDJ (Française des Jeux)minorChannel Partner/ Reseller/ DistributorState-owned lottery and gaming operator with ANJ license. Referenced for responsible gambling features like 'Pause 24h' option and lottery/gaming offerings.

Scale indicators4 records

Recent moves3 records

Expansion highlights3 records

Quantum Genomics competitors and assessment

Company assessment

Broad incumbents

  • Novartis: Global pharmaceutical leader with one of the largest cardiovascular franchises (Entresto, etc.). Represents the broad incumbent competitive backdrop against which a small cardiovascular specialist like Quantum Genomics must position.
  • AstraZeneca: Global pharma with a substantial cardiovascular, renal, and metabolism franchise (Farxiga, Brilinta). Represents a key incumbent competitor and a credible acquirer of differentiated cardiovascular assets that Quantum Genomics might seek to develop or partner.
  • Servier: Large French private pharmaceutical company with a long-standing cardiovascular franchise. Servier provides a domestic French peer benchmark and represents both a competitor and a potential partner/acquirer for a French-listed cardiovascular specialist like Quantum Genomics.
  • Bayer: Major pharmaceutical company with an established cardiovascular portfolio (Xarelto/Eliquis franchises). Bayer represents both a competitive threat and a potential strategic acquirer for focused cardiovascular specialists like Quantum Genomics.

Regional players

  • Valneva: French-listed specialty biotech focused on vaccines and infectious diseases. Comparable to Quantum Genomics as a fellow French-listed small-cap biotech with similar capital-markets dynamics and European biotech operating profile.
  • Innate Pharma: French-listed clinical-stage biotech developing immuno-oncology therapies. Comparable to Quantum Genomics as a French small-cap listed biotech serving as a relevant benchmark for European biotech capital-raising dynamics.
  • Genfit: French-listed clinical-stage biotech headquartered in France. As a fellow small-cap French biotech, Genfit provides a comparable benchmark for capital-markets dynamics, investor base, and European listing economics relevant to Quantum Genomics.
  • Abivax: French-listed clinical-stage biotech developing inflammatory disease therapies. Comparable to Quantum Genomics in size, listed status on Euronext, and small-team European biotech operating model, even though the therapeutic area differs.

Direct peers

  • Idorsia Pharmaceuticals: Swiss-listed specialty pharma focused on cardiovascular and central nervous system therapies with a small, R&D-heavy organization comparable to Quantum Genomics. Both companies target specialty indications with high unmet need and rely on capital markets to fund late-stage development.

Emerging players

  • Mineralys Therapeutics: US clinical-stage biotech developing therapies for resistant and uncontrolled hypertension — a directly comparable cardiovascular indication to Quantum Genomics' focus. Both companies target high-unmet-need cardiovascular subsegments with novel mechanisms.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Quantum Genomics social profiles

Digital presence

Quantum Genomics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Quantum Genomics leadership team

Management profile

Number of profiles

Profiles2 records

Quantum Genomics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Quantum Genomics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Quantum Genomics

What does Quantum Genomics do?

Quantum Genomics develops therapies for unmet medical needs in the field of cardiovascular diseases. The company focuses on biopharmaceutical research and development of novel drug compounds targeting hypertension and related cardiovascular conditions.

When was Quantum Genomics founded?

Quantum Genomics was founded in 2006. It employs 1 to 10 people.

Where is Quantum Genomics based?

Quantum Genomics is headquartered in Paris, France, in the Europe region.

How does Quantum Genomics make money?

Two revenue lines are on record. Affiliate Commissions are the primary driver. The others are advertising Revenue.

Who are Quantum Genomics's main competitors?

Broad incumbents on record are Novartis, AstraZeneca, Servier and Bayer. Regional players are Valneva, Innate Pharma, Genfit and Abivax. Idorsia Pharmaceuticals is listed as a direct peer. Mineralys Therapeutics is listed as an emerging player.

Does Quantum Genomics have an API?

No public API is recorded for Quantum Genomics.

What industry is Quantum Genomics in?

Quantum Genomics's product category is Cardiovascular Therapeutics. Its primary akta.pro industry code is HLAIACAG, Cardiology & Vascular Specialty Pharmaceuticals. Its NAICS code is 541714.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireQuantum Genomics Announces Lack of Significant Efficacy for Firibastat in Their Phase III Study, FRESH and is Redirecting to New DevelopmentsQuantum Genomics announced that firibastat failed to show significant efficacy versus placebo in its phase III study FRESH, leading to discontinuation of the REFRESH study and the drug's cardiovascular development. The company will reallocate 11 million euros to new treatments, with negotiations ongoing.GlobeNewswireBryan Garnier & Co Initiates the Coverage of Quantum Genomics with a Target Price at 13€ per ShareBryan Garnier & Co initiated coverage of Quantum Genomics with a buy recommendation and a 13€ per share target, valuing the company at 450M€. The target is set before the company's FRESH phase III study presentation at the American Heart Association in November 2022.GlobeNewswireQuantum Genomics Publishes its 2022 First Half Results andQuantum Genomics published its first half 2022 results, reporting a net loss of €8.8 million and operating income of €2.9 million. The company enrolled the last patient in its FRESH study, with results to be presented at the American Heart Association conference on November 7. It also completed a €17.5 million capital increase, boosting shareholder equity to €19.7 million.GlobeNewswireQuantum Genomics Announces That the Results Obtained with Firibastat in its Phase III Study, FRESH Will Now be Presented on November 7, 2022, During the AHA Conference in a Session Dedicated to ResistQuantum Genomics will present results of its phase III FRESH study on firibastat for resistant hypertension at the AHA conference on November 7, 2022. The study randomized 515 patients across 69 hospitals, and results will support registration filings with US and European authorities.GlobeNewswireQuantum Genomics announces the appointment of its new Scientific Advisory BoardQuantum Genomics appointed Professor George L. Bakris, Professor Gregory Y. H. Lip, and Professor Atul Pathak to its Scientific Advisory Board. The board will advise on clinical development and registration strategies for Firibastat, a drug targeting the brain for hypertension and heart failure, as the company approaches market launch.GlobeNewswireQuantum Genomics Announces the End of Patient Recruitment for its Phase III Pivotal Study FRESHQuantum Genomics announced completion of patient recruitment in its phase III pivotal study FRESH, which evaluates firibastat for difficult-to-treat hypertension. The study randomized patients across 69 hospitals, with primary endpoint being AOBP reduction after three months. Initial results are expected in late October 2022 for the AHA congress.GlobeNewswireQuantum Genomics Appoints Sarah Merlen Boulenger as Head of Regulatory AffairsQuantum Genomics appointed Sarah Merlen-Boulenger as Head of Regulatory Affairs to lead the preparation of firibastat's registration dossier for hypertension and heart failure. She will submit a New Drug Application to the FDA and a Marketing Authorization Application to the EMA. The company aims to launch the drug as a novel treatment for resistant hypertension.GlobeNewswireQuantum Genomics Publishes its Results for Fiscal YearQuantum Genomics reported its fiscal year 2021 results, with operating revenue of €3.2 million and a net loss of €16.6 million. The company completed a €17.5 million capital increase and aims to register firibastat for resistant hypertension by end of 2023.GlobeNewswireQuantum Genomics Announces Successful Capital Raise with a Gross Sum of Approximately 15.6M€Quantum Genomics raised approximately 15.6M€ by issuing new shares at a 15% discount, with Julphar subscribing $2M. The company will use proceeds to develop firibastat and explore new indications. Settlement is scheduled for April 29, 2022.GlobeNewswireQuantum Genomics Raises a Gross Amount of Approximately € 15 MQuantum Genomics launched a €15 million capital increase for institutional investors, receiving at least €12 million in commitments, including €10 million from Otium Capital. The funds will finance firibastat's development toward first registration by end of 2023 and explore new therapeutic fields. Julphar also subscribed to a separate reserved capital increase of $2 million.